Busy week ahead—lawsuits to file, meetings to attend, articles to write, and continuing legal education seminars to plan. So, we’ll keep this short:
- More on Aranesp, the anemia drug by Amgen: It is associated with increased risk of stroke in patients with diabetes and chronic kidney disease (courtesy @TomLamb and www.drug-injury.com).
- The FDA will discuss Merck’s cholesterol drugs Vytorin and Zetia as they relate to pediatric-focused safety reviews on November 18 in Maryland. See our prior blog post on the dangers of Vytorin and Zetia).
- A quick criminal history of Pfizer (courtesy @PharmaGossip). Are they more focused on saving lives than making money?
- A little on the merger between Merck and Schering-Plough and their new web issues (courtesy www.shearlingsplowed.blogspot.com).
- More on Accutane, which has been recalled in light of links to inflammatory bowel disease
- New Jersey considers giving mass tort status to the YAZ, Yasmin, and Ocella birth control injury litigation